AAIC 2026: Glial Cell Mechanisms
Conference: [AAIC 2026](/events/aaic-2026) | Dates: July 12-15, 2026 | Location: Excel London, UK
Overview
Glial cells—microglia and astrocytes—have emerged as central players in Alzheimer's disease pathogenesis and represent promising therapeutic targets. AAIC 2026 features extensive research on glial biology, reflecting the field's recognition that neurodegenerative processes involve complex non-neuronal interactions[@aao2026].
Microglia in Alzheimer's Disease
Disease-Associated Microglia (DAM)
Disease-associated microglia represent a distinct microglial activation state observed in Alzheimer's disease and other neurodegenerative conditions[@deczkowska2023]:
flowchart TD
A["Homeostatic Microglia"] --> B["Stage 1 DAM: TREM2-independent"]
B --> C["Stage 2 DAM: TREM2-dependent"]
C --> D["Neurodegeneration Associated"]
A -->|"Aging, Abeta"| B
B -->|"TREM2 activation"| C
C -->|"Chronic inflammation"| D
style A fill:#0a1929,stroke:#01579b,color:#e0e0e0
style B fill:#3e2200,stroke:#e65100,color:#e0e0e0
style C fill:#2d0f0f,stroke:#c62828,color:#e0e0e0
style D fill:#2d0f0f,stroke:#ad1457,color:#e0e0e0
Key DAM Characteristics:
- Stage 1 DAM: Initial response to amyloid pathology; TREM2-independent
- Stage 2 DAM: Requires TREM2 signaling; enhanced phagocytic capacity
- Stage 3 DAM: Associated with neurodegeneration; may become maladaptive
...AAIC 2026: Glial Cell Mechanisms
Conference: [AAIC 2026](/events/aaic-2026) | Dates: July 12-15, 2026 | Location: Excel London, UK
Overview
Glial cells—microglia and astrocytes—have emerged as central players in Alzheimer's disease pathogenesis and represent promising therapeutic targets. AAIC 2026 features extensive research on glial biology, reflecting the field's recognition that neurodegenerative processes involve complex non-neuronal interactions[@aao2026].
Microglia in Alzheimer's Disease
Disease-Associated Microglia (DAM)
Disease-associated microglia represent a distinct microglial activation state observed in Alzheimer's disease and other neurodegenerative conditions[@deczkowska2023]:
Mermaid diagram (expand to render)
Key DAM Characteristics:
- Stage 1 DAM: Initial response to amyloid pathology; TREM2-independent
- Stage 2 DAM: Requires TREM2 signaling; enhanced phagocytic capacity
- Stage 3 DAM: Associated with neurodegeneration; may become maladaptive
DAM Markers:
- Upregulated: [TYROBP](/genes/tyrobp), [CSF1](/genes/csf1), [APOE](/genes/apoe), [AXL](/genes/axl)
- Downregulated: [CX3CR1](/genes/cx3cr1), [P2RY12](/genes/p2ry12)
TREM2 Signaling Pathway
[TREM2](/proteins/trem2) (Triggering Receptor Expressed on Myeloid Cells 2) is a critical regulator of microglial function:
Mermaid diagram (expand to render)
TREM2 Variants and AD Risk:
| Variant | Risk Effect | Functional Impact |
|---------|-------------|-------------------|
| R47H | 3-4x increased | Impaired lipid sensing |
| R62H | 2-3x increased | Reduced ligand binding |
| T96I | 1.5-2x increased | Altered signaling |
TREM2-Targeting Therapies at AAIC 2026:
| Program | Company | Mechanism | Stage |
|---------|---------|-----------|-------|
| AL002 | Alector/GSK | TREM2 agonist | Phase II |
| PY314 | Pyroneer | TREM2 agonist | Phase I |
| SAR-443122 | Sanofi | TREM2 inverse agonist | Phase I |
See [TREM2 Microglia Pathway](/mechanisms/trem2-microglia-pathway) for detailed mechanism.
Microglial Priming
Microglial priming describes the sensitization of microglia to produce exaggerated inflammatory responses:
Priming Factors:
- Aging
- [APOE4](/genes/apoe4) allele carriage
- Previous neuroinflammatory events
- Systemic infection
Primed Microglia Characteristics:
- Enhanced baseline cytokine production
- Exaggerated response to secondary challenges
- Impaired surveillance function
CSF1R Targeting
[CSF1R](/proteins/csf1r) (Colony Stimulating Factor 1 Receptor) regulates microglial survival and proliferation:
Mermaid diagram (expand to render)
Clinical Considerations:
- CSF1R blockade reduces microglial numbers
- Risk of impairing beneficial surveillance functions
- May need cell-type specific targeting
Complement System in Neurodegeneration
The complement system mediates synaptic elimination by microglia:
Mermaid diagram (expand to render)
Complement Therapeutics
| Target | Drug | Company | Status |
|--------|------|---------|--------|
| C1q | ANX007 | Annexon | Phase II |
| C3 | Pegcetacoplan | Apellis | Phase II |
| C5 | Eculizumab | Alexion | Pilot |
See [Complement-Mediated Synapse Loss](/mechanisms/complement-mediated-synapse-loss).
Astrocyte Reactivity
[Reactive astrocytes](/cell-types/reactive-astrocytes-overview) adopt distinct phenotypes in neurodegeneration[@liddelow2017]:
A1 vs A2 Classification
Mermaid diagram (expand to render)
A1 Astrocyte Markers:
- [GFAP](/proteins/gfap) (general marker)
- [S100A10](/proteins/s100a10)
- [Serpina3n](/genes/serpina3n)
A2 Astrocyte Markers:
- [S100A4](/proteins/s100a4)
- [CD44](/genes/cd44)
- [Vim](/genes/vim)
Astrocyte-Neuron Interactions
Neurotoxic Effects:
- Impaired [glutamate](/mechanisms/glutamate-excitotoxicity) homeostasis (reduced EAAT1/2)
- Release of pro-inflammatory cytokines
- Complement component production
Therapeutic Implications:
- Block A1-inducing factors (IL-1α, TNF, C1q)
- Promote A2 phenotype conversion
- Enhance astrocyte support functions
Glial Crosstalk
Microglia-Astrocyte Communication
Mermaid diagram (expand to render)
Neuroimmune Cross-Talk
Gut-Brain Axis:
- [Microbiome](/mechanisms/microbiome-gut-brain-axis)-derived SCFAs modulate glial function
- Leaky gut increases systemic LPS triggering CNS inflammation
- Microbiome signatures differ in AD vs. controls
Peripheral Immune System:
- [Monocyte](/cell-types/monocytes) infiltration (CCR2+)
- [NK cell](/cell-types/natural-killer-cells) dysfunction
- [T cell](/cell-types/t-cells) infiltration (CD8+, CD4+)
Therapeutic Targeting of Glial Cells
Current Approaches
| Strategy | Target | Approach | Stage |
|----------|--------|----------|-------|
| TREM2 agonism | TREM2 | Enhance phagocytosis | Phase II |
| CSF1R inhibition | CSF1R | Reduce DAM | Preclinical |
| Complement inhibition | C1q, C3 | Prevent synapse loss | Phase II |
| Astrocyte modulation | A1→A2 shift | Reprogram phenotype | Preclinical |
Emerging Strategies
- Microglial replacement: Bone marrow transplant approaches
- Glial progenitor targeting: Induced pluripotent stem cell-derived glia
- Gene therapy: Modulate glial gene expression in vivo
Glial Biomarkers
Microglial Biomarkers
| Biomarker | Source | Significance |
|-----------|--------|--------------|
| [sTREM2](/proteins/trem2) | CSF/Plasma | TREM2 shedding, disease progression |
| [YKL-40](/proteins/ykl40) | CSF/Plasma | Astrocyte activation |
| [IBA1](/proteins/iba1) | Tissue | Microglial activation marker |
Astrocyte Biomarkers
| Biomarker | Source | Significance |
|-----------|--------|--------------|
| [GFAP](/proteins/gfap) | Plasma | Reactive astrogliosis |
| S100B | CSF/Plasma | Astrocyte damage |
Notable Sessions at AAIC 2026
Symposia
- "Microglia in Alzheimer's Disease: From Biology to Therapeutics"
- "Astrocyte Reactivity: Good, Bad, or Both?"
- "Complement-Mediated Synaptic Loss: New Therapeutic Targets"
Workshops
- "Glial Cell Models for Drug Discovery"
- "In Vivo Imaging of Glial Activation"
Related NeuroWiki Content
- [Neuroinflammation in AD](/mechanisms/neuroinflammation-ad-pd-als)
- [TREM2 Signaling Pathway](/mechanisms/trem2-signaling)
- [Disease-Associated Microglia](/cell-types/disease-associated-microglia)
- [Reactive Astrocytes Overview](/cell-types/reactive-astrocytes-overview)
- [Complement System Pathway](/mechanisms/complement-system-pathway)
- [AAIC 2026: Neuroinflammation](/events/aaic-2026/neuroinflammation)
See Also
- [AAIC 2026 Conference](/events/aaic-2026)
- [AAIC 2026 Emerging Therapeutic Targets](/events/aaic-2026-emerging-therapeutic-targets)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Microglia in Neurodegeneration](/entities/microglia-in-neurodegeneration)
References
[Wang S, et al., Microglia in Alzheimer's disease: from pathogenesis to therapeutic targeting. Signal Transduct Target Ther. 2023 (2023)](https://doi.org/10.1038/s41392-023-01428-9)
[Deczkowska A, et al., Disease-associated microglia: A universal target for neurodegeneration. Cell. 2023 (2023)](https://doi.org/10.1016/j.cell.2023.09.012)
[Liddelow SA, et al., Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017 (2017)](https://doi.org/10.1038/nature21359)